EFFECTIVENESS OF THE ANTIVIRAL DRUG RUTAN ON THE COURSE OF ADJUVANT-INDUCED ARTHRITIS.

Authors

  • Ziyaviddin Z. Khakimov
  • Alisher Rh. Rakhmanov

Abstract

Objectives. This study aims to investigate the impact of Rutan, a polyphenolic compound with high antiviral and anti-inflammatory activity, on adjuvant arthritis.

Methods. Experimental studies were conducted on sexually mature white rats to develop a model of adjuvant-induced arthritis in laboratory animals. The study involved injecting 0.1 ml of complete Freund's adjuvant (CFA) into the hind paw of the rats. The aim was to study the prophylactic and therapeutic effect of different doses of Rutan and diclofenac sodium. The paw edema was measured before and after the drug administration, and blood samples were collected to identify pro- and anti-inflammatory interleukins, tumor necrosis factor, and C-reactive protein.

Results. Rutan has shown anti-inflammatory activity (AIA) with prophylactic application, resulting in 27.5%, 30.9%, and 34.8% AIA on days 7, 10, and 14, respectively. The therapeutic application resulted in AIA of 24.1% on day 28 compared to the control group. Prophylactic use of Rutan and diclofenac sodium reduced IL-1 levels by 77.3% and 71.4%, TNFα by 69.9% and 73.6%, and CRP by 77.1% and 80.5%, while increasing IL-10 levels by 64.5% and 75.2%, respectively. Rutan and diclofenac treatment group showed similar results, with IL-1 levels decreasing by 74.6% and 79.8%, TNFα by 65.5% and 70.3%, and CRP by 83.8% and 87.4%, while increasing IL-10 levels by 48.3% and 69.0%, respectively.

Conclusions. Rutan shows strong pharmacological activity in inhibiting inflammation in rats with arthritis, comparable to diclofenac sodium.

Read More

Downloads

Submitted

2024-06-02

Published

2024-06-02